Loading company
Aurinia Pharmaceuticals Inc.
AUPH · Nasdaq · ·
Next earnings: November 3, 2026
$16.43-0.5%Sep 29 close
- 1M
- +0.9%
- 6M
- +17.5%
- 1Y
- +48.7%
- 5Y
- -30.2%
AUPH · Nasdaq · ·
Next earnings: November 3, 2026
$16.43-0.5%Sep 29 close
Aurinia Pharmaceuticals Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $83.2M | $70M | +18.87% |
| Profit | $37.4M | $21.5M | +73.91% |
| Profit per share | $0.28 | $0.16 | +75.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Aurinia Pharmaceuticals Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Aurinia Pharmaceuticals Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.